Retatrutide
An investigational triple agonist acting on GIP, GLP-1, and glucagon receptors simultaneously, the most mechanistically complex incretin candidate in the class.
Research status: Phase 3 trials underway; not yet FDA-approved.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
Selected references
- New England Journal of Medicine · 2023 Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
- The Lancet · 2023 Retatrutide for People with Type 2 Diabetes — A Phase 2 Trial
- Nature Medicine · 2024 Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease
- Lancet Diabetes & Endocrinology · 2025 Effects of Retatrutide on Body Composition
- Eli Lilly · 2025 TRIUMPH-4 Phase 3 Trial Results
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.
Related in Weight Loss